FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCL

The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Professionals Analyze Pathology Following lung Lobectomies for Adenocarcinoma

Researchers examined the pathology of early-phase COVID-19 pneumonia in two older patients who were admitted to the hospital for adenocarcinoma procedures, but did not exhibit COVID-19 symptoms at the time of these procedures.

Moving toward Nonchemotherapy-Based Approaches in Follicular Lymphoma

Michael L. Grossbard, MD, suggested that chemo-free regimens, including PI3K inhibitors and a more widespread use of allogeneic stem cell transplant, are being explored as treatment options in this space.

Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment

A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort.

Venetoclax with Azacytidine Improved Overall Survival for Patients with AML

Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia.

AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19

AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection.